The trial leaders will present the results of the Dana-Farber Cancer Institute ALL Consortium study, which involved nearly 500 patients under age 18 with B-precursor acute lymphoblastic leukemia (B-ALL), at the annual meeting of the American Society of Hematology (ASH) conference.
Trial participants received an initial course of "induction" chemotherapy for B-ALL, a cancer of the blood that is one of the most common cancers in children below age 15. After a month of treatment, the patients had a bone marrow sample sent for a test able to measure levels of leukemia that cannot be seen under a microscope.
Thirty-five of the patients were deemed to have a very high risk of relapsing because they retained relatively large numbers of leukemia cells as measured by this test. An additional 16 patients were also considered very high-risk because their leukemia cells had certain chromosomal abnormalities.
These 51 patients then received an intensified treatment regimen consisting of two additional rounds of chemotherapy using agents not typically given to newly diagnosed patients with B-ALL. This was followed by an intensified consolidation phase of therapy to keep the disease in remission, and then a standard maintenance phase to further deter the disease from returning.Investigators estimate that, five years after reaching complete remission, the rate of event-free survival (a measure of survival without relapse or development of another cancer) was 76 percent for these very high-risk patients. By contrast, less than half of similar patients who receive standard chemotherapy reach the five-year mark without relapsing.
"Though it involved a relatively small number of patients, the new trial is one of the first to show improved outcomes for this set of patients as a result of an intensified chemotherapy protocol," says senior author Lewis Silverman, MD, of Dana-Farber/Children's Hospital Cancer Center. Trial leaders will continue to track the study participants to gauge the durability of the remissions produced by the intensified treatment.
Co-authors of the study include Kristen Stevenson, MS, and Donna Neuberg, ScD, of Dana-Farber; Marian Harris, MD, of Boston Children's Hospital; and Stephen Sallan, MD, of Dana-Farber/Children's Hospital Cancer Center.Dana-Farber/Children's Hospital Cancer Center
Boston Children's is also the site of DF/CHCC inpatient clinical translational research in pediatric malignancies and has long supported the operation of an effective and productive stem cell transplant service. It has a long history of investment in and support of both clinical and basic cancer research, with more than $7.3 million in National Cancer Institute research support and 47,000 square feet of space devoted to cancer research. It is a recognized center of excellence in angiogenesis, cellular/molecular immunology, cancer genetics, and molecular signaling research.
Teresa Herbert | EurekAlert!
Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University
3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences